source: American Society of Hematology

year: 2016

authors: Sophie Lanzkron, Carlton Haywood Jr., Jane A Little, Joshua Field, Joseph Ryan Shows, Jodi Segal, Mustapha Saheed, Derek Robertson, Marc V Proudford, Adrienne Kincaid, Lorri Burgess, Charles Green, Hang Wang, Rebecca Seufert, Jasmine Brooks, Brandi Griffin, Allie Piehet, Steven Frymark, Ravi Varadhan

Background: We undertook a large multisite observational study collecting prospective data on health care utilization of patients with sickle cell disease (SCD). No prospective examination of symptom burden has been undertaken in SCD since the Cooperative Study of Sickle Cell Disease, and none in the modern era, since the widespread adoption of hydroxyurea therapy. The ESCAPED trial aims to compare patient centered outcomes following management of acute painful vaso-occlusive (VOC) events in the emergency department or in the infusion center. Here, we examine acute care utilization patterns in the first 223 subjects who have completed at least 6 months of follow-up and test determinants of utilization.
Methods: This is an ongoing, prospective cohort study that is recruiting across four sites (Baltimore, Cleveland, Milwaukee, and Baton Rouge). 500 adults with SCD who live in proximity to one of the study sites are being recruited and followed for 18 months. Data from visits for all acute, uncomplicated VOC are collected by chart review and patient interview. To ensure that acute visits are not missed, subjects are contacted on a monthly basis and where available statewide health information exchanges are queried. We tested for associations between subject characteristics upon enrollment and the number of acute visits during follow up using Poisson regression.

Share

Discuss in Social Wall

Twitter

Share to SCDteam

+myBinder